Business
TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results
– Q4 sales of approximately $5.7 million represent 77% growth versus 2022 – – Q4 and full year gross margin of approximately 90% and 86% respectively – –
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":"\n– Q4 sales of approximately $5.7 million represent 77% growth versus 2022 –\n– Q4 and full year gross margin of approximately 90% and 86% respectively –\n– Full year 2024 sales growth expected to exceed 50% –\n\n\n– Conference call scheduled for Monday, April 1, 2024, at 9:00 a.m. ET –\n\n\n DENVER--(BUSINESS WIRE)--\nTriSalus Life Sciences® Inc. (Nasdaq: TLSI) announced today that the Company will host a conference call and webcast on April 1, 2024, at 9:00 a.m. ET to discuss financial results for the fourth quarter and full year ended December 31, 2023, and provide a business update. A press release detailing the fourth quarter and full year results will be issued prior to the call.\n\n\nPreliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Results\n\n\nFull financial results for the year ended December 31, 2023, are in the process of being finalized, however initial and preliminary results show revenue, driven solely by the TriNav® Infusion System, are expected to be approximately $5.7 million for the fourth quarter of 2023. This represents growth of approximately 77% versus the fourth quarter of 2022.\n\n\nFor the full year 2023, TriSalus expects to report revenue of approximately $18.5 million. This represents growth of approximately 49% versus the full year 2022. The Company believes this strong momentum will continue and expects sales to grow in excess of 50% in 2024.\n\n\nThe Company anticipates gross margin will be approximately 90% for the fourth quarter and 86% for the full year 2023, reflecting a notable improvement compared to 75% and 82% respectively, for the same periods in 2022.\n\n\nTriSalus also expects to report cash and cash equivalents balances of approximately $11.8 million as of December 31, 2023. It expects to have sufficient liquidity to fund operations into the second quarter of 2024. The Company is currently in the process of obtaining additional liquidity to fund operations through 2024.\n\n\nConference Call Details\n\n\nThe event will be webcast live on the investor relations section of TriSalus’ website at https://investors.trisaluslifesci.com/news-events/events-presentations. Following the conclusion of the event, a webcast replay will be available on the website for approximately 90 days. Interested parties participating by phone will need to register using this online form. After r...